Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Call Center Functionality for Digital Medicine System (Abilify MyCite)
NCT02722967Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Mar 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aripiprazole in schizophrenia, major depressive disorder (MDD), bipolar I disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Mar 2016; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophreniamajor depressive disorder (MDD)bipolar I disorder
Beyond the preview
Go deeper on NCT02722967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02722967.